Hypnogen (Zolpidem Tartrate)

Zolpidem binds selectively to the benzodiazepine site of the GABAA receptor, enhancing the inhibitory action of the neurotransmitter GABA. This increased chloride influx hyperpolarises neurons, reducing central nervous system activity and facilitating the onset of sleep.

The appropriate dose of Hypnogen is determined by the prescribing clinician based on the patient’s age, health status, and response to therapy. Dosage instructions are provided on the prescription label and should be followed exactly as directed.

Zolpidem is classified as a pregnancy‑category drug only when the potential benefit justifies the potential risk to the fetus. It is generally recommended to avoid use during pregnancy and breastfeeding unless absolutely necessary, and the decision should be made by a qualified healthcare professional.

To order Hypnogen, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with benzodiazepine hypnotics, zolpidem has a shorter half‑life and a more selective binding profile, which generally results in less next‑day sedation. However, it shares similar cautions regarding dependence, complex sleep behaviours, and interactions with other central nervous system depressants.

Hypnogen should be stored at ambient temperature, below 25 °C. Keep the tablets in the original packaging, protect them from moisture, heat and direct sunlight, and ensure they are out of reach of children.

Hypnogen is taken orally, usually shortly before bedtime. The tablet should be swallowed whole with a glass of water and taken only when the patient can obtain a full night’s sleep (7‑8 hours) before needing to be active again.

Serious risks include complex sleep‑related behaviours such as sleepwalking or driving while not fully awake, severe allergic reactions, depression or suicidal thoughts, and respiratory depression when combined with other CNS depressants. Patients should seek immediate medical attention if any of these occur.

Hypnogen is contraindicated in patients with known hypersensitivity to zolpidem or any tablet excipients, those with severe hepatic impairment, and individuals who have experienced complex sleep behaviours with zolpidem previously. It should also be avoided in patients taking strong CYP3A4 inhibitors without medical supervision.